AstraZeneca: licensing agreement with RQ Biotechnology

(CercleFinance.com) - AstraZeneca announces that it has entered into a licensing agreement with RQ Biotechnology for a portfolio of early stage monoclonal antibodies (mAbs) targeting SARS-CoV-2, the virus that causes Covid-19.


As part of the agreement, AstraZeneca has acquired an exclusive worldwide licence to develop, manufacture and market mAbs against SARS-CoV-2.

RQ Bio is a British biotechnology company that develops treatments and preventive therapies based on potent broad-spectrum mAbs to address unmet needs in vulnerable patient populations.


Copyright (c) 2022 CercleFinance.com. All rights reserved.